{"id":"NCT01634152","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2012-07-06","resultsPosted":"2015-12-21","lastUpdate":"2016-01-29"},"enrollment":401,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Tiotropium low dose mcg","otherNames":[]},{"type":"DRUG","name":"Tiotropium high dose","otherNames":[]}],"arms":[{"label":"Placebo QD","type":"PLACEBO_COMPARATOR"},{"label":"Tiotropium low dose QD","type":"EXPERIMENTAL"},{"label":"Tiotropium medium dose QD","type":"EXPERIMENTAL"}],"summary":"The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in children (6 to 11 years old) with severe persistent asthma.","primaryOutcome":{"measure":"FEV1 Peak(0-3h) Change From Baseline","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Placebo Respimat","deltaMin":0.252,"sd":0.025},{"arm":"Tio R2.5","deltaMin":0.287,"sd":0.025},{"arm":"Tio R5","deltaMin":0.391,"sd":0.026}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2724"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":94,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Czechia","Germany","Guatemala","Hungary","Latvia","Lithuania","Poland","Romania","Russia","Slovakia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":134},"commonTop":["Asthma","Peak expiratory flow rate decreased","Nasopharyngitis"]}}